Rasburicase
- Generic Name
- Rasburicase
- Brand Names
- Elitek, Fasturtec
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 134774-45-1
- Unique Ingredient Identifier
- 08GY9K1EUO
- Background
Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
- Indication
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
- Associated Conditions
- Hyperuricemia
- Associated Therapies
- -
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- Drug: busulfanDrug: cyclophosphamideDrug: cyclosporin-ADrug: etoposideDrug: methotrexateDrug: rasburicaseDrug: sirolimusProcedure: allogeneic hematopoietic stem cell transplantationDrug: tacrolimusProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiationDrug: fludarabineDrug: allopurinol
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00513474
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00360438
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Rasburicase in Tumor Lysis Syndrome
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 33
- Registration Number
- NCT00302653
- Locations
- 🇧🇷
Sanofi-aventis administrative office, São Paulo, Brazil
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 80
- Registration Number
- NCT00199043
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00186940
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University, Palo Alto, California, United States
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
- Conditions
- Childhood Immunoblastic Large Cell LymphomaChildhood Diffuse Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaStage I Childhood Large Cell LymphomaStage III Childhood Large Cell LymphomaStage IV Childhood Large Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: methotrexateDrug: leucovorin calciumDrug: rasburicaseDrug: prednisoneDrug: methylprednisoloneBiological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: vincristine sulfateDrug: hydrocortisone sodium succinateOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00057811
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.